EMA Authorised: Spinraza (nusinersen sodium) — Biogen Netherlands B.V.

View source ↗

Summary

EMA authorises Spinraza (nusinersen) for spinal muscular atrophy, granted orphan medicine status with accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Spinraza (nusinersen)

Snippet

Status: Authorised. Therapeutic area: Muscular Atrophy, Spinal. MAH: Biogen Netherlands B.V.. Decision date: 09/07/2026. Orphan medicine. Accelerated assessment